DO-BO

LEADING EMPLOYER 2025

We are proud to officially announce that MArS Market Access & Pricing Strategy has been recognized as one of the LEADING EMPLOYERS, ranking us within the top 1% of companies across Germany!

With flexibility, innovation and respect defining how we work together, this award reflects our strong company culture. Together we cultivate a thriving environment through: flexible working hours, digital coffee breaks & team bonding, a culture of trust, mutual respect and diversity as well as innovation-driven solutions, including AI-powered platforms. We believe that happy and empowered employees drive success!

It’s been an incredible journey for us, starting as a D-A-CH-focused consultancy to expanding globally with AI-driven training solutions – and this recognition motivates us to keep pushing boundaries in market access, pricing, and beyond. A huge thank you to our entire team – this award belongs to all of you!

Related

In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour, Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutzen-Analysen? Wo drohen Fehlanreize für innovative Arzneimittel, […]

From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast, Dr. Stefan Walzer interviews Livia Altmann, a former Swiss Olympic ice hockey player who has transitioned into a leadership and “Human Intelligence 2.0” expert. Together, they explore how […]

In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly […]